FDA Reclassifies TENS Device for Fibromyalgia Treatment

The U.S. FDA has categorized transcutaneous electrical nerve stimulators (TENS) for fibromyalgia into Class II, subject to special controls. This regulatory adjustment is intended to ensure the device's safety and effectiveness while streamlining its availability to patients. The reclassification aims to reduce regulatory hurdles and improve access to this treatment option.